Aripiprazole: Initial clinical experience with 142 hospitalized psychiatric patients

Journal of Psychiatric Practice

Volumn 11, Issue 4, 2005, Pages 241-247

  Centorrino, Franca ^a   Fogarty, Kate V ^a   Cimbolli, Paola ^a   Salvatore, Paola ^a   Thompson, Terri Ann ^a   Sani, Gabriele ^a   Cincotta, Stephanie L ^a   Baldessarini, Ross J ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic; Bipolar disorder; Drug dosing; Schizophrenia; Second generation antipsychotic

Indexed keywords

ARIPIPRAZOLE; DEHYDROARIPIPRAZOLE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DRUG METABOLITE; NEUROLEPTIC AGENT; TRANQUILIZER; UNCLASSIFIED DRUG;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; BODY WEIGHT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; DELIRIUM; DEMENTIA; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERABILITY; DYSTONIA; FEMALE; HOSPITAL PATIENT; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR AFFECTIVE DISORDER; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; SEDATION; SIDE EFFECT; SYNCOPE;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY WEIGHT; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; MALE; MATHEMATICAL COMPUTING; MIDDLE AGED; OBESITY; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING; PSYCHOTIC DISORDERS; QUINOLONES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 23744476414     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200507000-00004     Document Type: Article

References (20)

1. Abilify (aripiprazole) NDA, 22 November 2002. www.fda.gov/cder/foi/ appletter/2002/21436ltr.pdf
2. Abilify product information. New York: Bristol-Myers Squibb Company (www.abilify.com).
3. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: A placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56.
4. Neumeyer JL, Booth RG, Baldessarini RJ. Therapeutic and diagnostic agents for Parkinson's disease. In: Abraham D, ed. Burger's medicinal chemistry and drug discovery, 6th edition. New York: John Wiley & Sons; 2003:711-41.
5. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
6. Winans E. Aripiprazole. Am J Health-Syst Pharm 2003;60:2437-45.
7. Meltzer HY, Li Z, Kaneda Y, et al. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsycho pharmacol Biol Psychiatry 2003;27:1159-72.
8. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffectve disorder. J Clin Psychiatry 2002;63:763-71.
9. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new typical antipsychotic: Phase 2 clinical trial result. Eur Neuropsycho pharmacol 1997;7(suppl 2):S227.
10. Petrie JL, Saha AR, Ali MW. Safety and efficacy profile of aripiprazole, a novel antipsychotic. Int J Neuropsychopharm 2000;3(suppl 1):S157.
11. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76
12. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37.
13. Keck PE, Marcus R, Tourkodimitrius S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-7.
14. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: Reliability, validity, and sensitivity. Br J Psychiatry 1978;133:429-35.
15. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): The CGI-BP. Psychiatry Res 1997;73:159-71.
16. Guy W. Clinical global impressions. In: ECDEU Assessment Manual for Psychopharmacology. U.S. Dept. Health, Education and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-22.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000:32-4.
18. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology 2003;166:391-9.
19. Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: Critical review of reported cases. J Clin Psychiatry 2000;61:649-55.
20. Baldassano CF, Ballas C, Datto SM, et al. Ziprasidone-associated mania: Case series and review of the mechanism. Bipolar Disord 2003;5:72-5.